Status:

NOT_YET_RECRUITING

Evaluating the Impact of Psychotherapeutic Advertising Claims on Cannabis Purchasing

Lead Sponsor:

Trustees of Dartmouth College

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

Conditions:

Anxiety

Depression

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have n...

Detailed Description

The U.S. legal cannabis industry increasingly uses psychotherapeutic advertising claims (PACs) on its websites to promote products that contain Δ⁹-tetrahydrocannabinol (THC; the primary intoxicant in ...

Eligibility Criteria

Inclusion

  • Age 21 years or older
  • Current residence in the United States
  • Cannabis use on 1-100 days in the past year
  • Current symptoms of mild to severe depression and/or generalized anxiety disorder, assessed by PHQ-8 (score ≥ 5) and GAD-7 (score ≥ 5)

Exclusion

  • Under 21 years of age
  • Not currently residing in the United States

Key Trial Info

Start Date :

January 30 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2026

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT07216911

Start Date

January 30 2026

End Date

July 31 2026

Last Update

October 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth College

Lebanon, New Hampshire, United States, 03766